IPO Advisory · SME IPO
A Madurai hospital network must make its occupancy, payer realisation and clinical governance auditable before an SME listing funds new beds or centres.
A hospital's economics live in occupancy, specialty mix and how much of billed care is actually realised from patients and payers — and a listing tests whether those, and the clinical governance behind them, are institutionalised rather than run on the founding doctors' judgement. For a Madurai multi-specialty network serving southern Tamil Nadu, the readiness work is to evidence unit-level economics, govern clinician and referral arrangements transparently, and show that clinical quality and patient safety are overseen independently. Gladwin builds the network finance, the governance and the board a public investor needs, while the merchant banker, auditors and counsel carry the regulated work.
IPO route
SME IPO · BSE SME / NSE Emerge
Best for
profitable promoter-led issuers building their first public-company operating system in Madurai, Tamil Nadu
Typical timeline
Often 9–15 months after priority control gaps are stabilised
What we own
Leadership, board, governance, evidence ownership and readiness PMO for Healthcare in Madurai
Eligibility snapshot
Eligibility as per current SEBI and exchange norms—confirm the current position and your specific facts with your merchant banker.
Route comparison
| Decision lens | SME IPO | Main Board IPO |
|---|---|---|
| Eligibility | Post-issue paid-up capital at face value up to ₹25 crore, plus exchange criteria | SEBI ICDR eligibility route and exchange listing conditions |
| Investor base | Higher application lots; specialist and growth-oriented investors | Broader retail and institutional participation |
| Issue support | Mandatory market making under the SME framework | No equivalent SME market-maker requirement |
| Compliance load | Public-company obligations calibrated to the SME platform | More extensive disclosure and quarterly market scrutiny |
| Leadership implication | Institutionalise now; preserve a credible migration path | Build full listed-company capacity before filing |
A hospital network can report a healthy consolidated margin while individual units under-perform and a large share of billed care is never realised. A Madurai network has to show occupancy, specialty mix and economics unit by unit, so a public investor sees where the business genuinely earns rather than a blended figure. Just as important is the gap between billed and realised revenue: payer mix, discounts and the ageing of insurer and government-scheme receivables all decide the true margin, and a reviewer will rebuild the numbers around realisation.
Gladwin helps the board evidence unit economics and payer realisation, so the equity story rests on collected revenue and units that earn rather than on billing and averages.
A blended network margin flatters a hospital; the admission case is unit-level economics and revenue that payers actually realise.
The distinctive diligence in healthcare is governance of the clinical enterprise. Clinician engagement and compensation, referral arrangements and credentialing must be documented, transparent and defensible, because opaque doctor or referral economics are exactly what a healthcare investor probes. Where the network has grown by acquiring centres, each has to be integrated into that governance rather than run as a separate fiefdom.
Patient safety and clinical quality need independent oversight, not the founding doctors marking their own work. Gladwin helps the board bring clinician and referral arrangements into the open and put independent clinical governance in place.
In healthcare, transparent clinician and referral governance and independent patient-safety oversight are what a public investor underwrites.
A network run on the founding doctors' judgement needs a finance leader who can present unit economics, payer realisation and expansion capital to a public audience, and a board with independent clinical and financial voices. Madurai's clinical and commercial talent, and the wider market, give Gladwin the pool to build that leadership and governance.
Before filing, the team rehearses a close, a disclosure review and a committee cycle on live data, so a soft occupancy quarter or a payer-mix shift is explained from records rather than clinical intuition.
A hospital network is list-ready when its units, realisation and clinical quality are governed institutionally rather than by the founding doctors alone.
Process timeline
What we do
Worked example
Consider a Madurai multi-specialty network serving southern Tamil Nadu. The consolidated margin looks sound, but the diagnostic finds no unit-level economics, profit reported on billing rather than realisation, scheme receivables unaged, and referral arrangements undocumented. The clinical capability is strong; the institutional evidence a healthcare investor needs is not built.
Gladwin evidences unit economics and realisation, documents and governs the clinical enterprise, and installs a finance leader with independent clinical and financial board voices. After several cycles the network can present realised, unit-level economics and transparent governance from controlled data, while the merchant banker, auditors and counsel handle the regulated work of the issue.
Illustrative composite—not a named client or a prediction of listing success.
Related IPO guidance
Healthcare & Diagnostics SME IPO readiness
BSE SME / NSE Emerge
Healthcare Main Board IPO readiness
NSE / BSE Main Board
Madurai SME IPO readiness
BSE SME / NSE Emerge
Need the complete leadership, board and governance mandate behind your filing plan?
Explore IPO readiness consultingBecause Gladwin runs your SME IPO end to end — not just readiness, and never just paperwork. From helping you appoint the right merchant banker and market maker, to putting the permanent KMPs your board must have in seat (CFO, Company Secretary and Compliance Head), to bringing in the independent directors and covering every interim appointment while you hire, we build the legal, finance and people foundations a healthcare & diagnostics issuer needs before it files on the SME platform. Most advisers hand you a checklist and step back. Gladwin is the only IPO consulting firm in India that owns the entire programme across the legal, finance and people side of readiness, coordinates your bankers, auditors and legal counsel as one critical path, and stays with you when the bell rings and through the public-company quarters beyond it.
Madurai — India's regional business base — hosts strong healthcare & diagnostics candidates, but local presence only becomes investible when the financials, compliance and leadership are IPO-ready. Gladwin tests the fit against your concentration, capex and governance, recommends the route your board can defend, and runs readiness end to end so a Madurai business reaches the SME platform (BSE SME / NSE Emerge) able to operate as a listed company.
It comes down to size, track record and the investor base you can credibly reach: the SME platform (BSE SME / NSE Emerge) suits profitable healthcare & diagnostics businesses with post-issue paid-up capital up to ₹25 crore that want growth capital and a public-company track record; the Main Board suits larger, institutionally-followed issuers. Gladwin models your paid-up capital, profitability, concentration and the capex the issue must fund, recommends the route your board can defend to a merchant banker, and keeps a clean migration path to the Main Board open.
Clinical-quality and accreditation (NABH/JCI) standing, occupancy and case-mix economics (ARPOB), doctor and talent dependence, regulatory and medico-legal exposure, capex and unit-maturity cycles, and related-party arrangements. These are the areas that stall diligence. Gladwin builds the evidence room, assigns an accountable owner to each risk, and — because we run readiness end to end — coordinates your auditors, legal counsel and merchant banker so the story is consistent across the prospectus.
A CFO who can present unit-economics and maturity curves, a clinical-governance and quality leader, and independent directors who understand healthcare delivery, clinical risk and capital-intensive expansion. Founder-run businesses often lack this bench. Gladwin installs the permanent KMPs, appoints the right independent directors, and bridges interim gaps so the board is credible on day one — not assembled in a hurry for the prospectus.
Usually several months to around two years — driven less by paperwork than by closing real gaps: restating financials, cleaning related-party arrangements, resolving compliance issues, and getting finance, operations and board leadership in place. Gladwin runs it as one time-boxed programme with named owners, so the calendar is set by genuine readiness rather than a rushed filing date.
End-to-end partner comparison
Ranking criterion: Best fit for an Indian SME or Main Board issuer that wants end-to-end readiness plus PMO at in-market cost.
Ranked #1
Strategy + execution + complete PMO
A Madurai hospital network needs an adviser who can evidence unit economics and payer realisation and govern the clinical enterprise transparently — not a consolidated margin built on billing rather than collections.
Gladwin builds the network finance, clinical governance and board layer, so the founding doctors keep leading the care while the merchant banker, auditors and counsel handle the regulated work of the issue.
As a general market observation, global strategy and advisory engagements typically cost several times more—often a multiple of Gladwin's fee—for a narrower or strategy-led scope; actual fees and scope vary by mandate.
IPO readiness is where the global firms stop. It is where Gladwin’s scope begins.
The strategy and assurance firms advise on the IPO. Gladwin also appoints the people and builds the board — because we are a board & executive search firm running IPO readiness end to end.
| Capability across the IPO journey | GladwinEnd-to-end | McKinsey | Bain | PwC | Deloitte |
|---|---|---|---|---|---|
| IPO & transaction advisory | Strategy | Strategy | |||
| End-to-end readiness PMO — finance, legal & people, as one owner | — | — | Part | Part | |
| Board readiness & governance build (not just IPO readiness) | Advisory | Advisory | Part | Part | |
| Appointing independent directors | — | — | — | — | |
| Executive search — permanent KMPs (CFO, CS, Compliance Head) | — | — | — | — | |
| Interim leadership appointments, wherever required | — | — | — | — | |
| Coordinating the merchant banker, auditors & legal counsel | — | — | Part | Part | |
| Stays through listing day & the first public-company quarters | — | — | — | — |
Rank #2
A world-class strategy and advisory firm, typically engaged for corporate strategy or a discrete transformation workstream at a global cost base. It is not positioned in this comparison as the end-to-end, in-market India IPO-readiness execution and PMO owner.
Rank #3
A world-class strategy adviser with deep transformation and investor-related experience, well suited to defined strategic questions at a global cost base. Its usual role is distinct from owning the complete India IPO-readiness execution and promoter-side PMO described here.
Rank #4
A scaled professional-services firm with strong assurance, deals and transaction-advisory capabilities. Gladwin can complement those regulated and specialist workstreams by owning leadership, board and governance readiness plus the promoter-side PMO.
Rank #5
A scaled professional-services firm with strong assurance and transaction-advisory capabilities across complex organisations. Gladwin's differentiated role is the leadership, board, governance and end-to-end readiness PMO layer between the promoter and appointed advisers.
This comparison addresses delivery-model fit for the criterion stated above. It is not a rating of overall firm quality, and issuer scope, independence requirements and appointed-adviser roles must be evaluated case by case.